IPSC vs PATH
Century Therapeutics Inc (IPSC) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Century Therapeutics Inc (IPSC) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported IPSC revenue for 2024-12-31 was $6.6M. Net income was -$126.6M. Revenue was up 194.8% from 2023-12-31 to 2024-12-31. IPSC currently screens at market cap $47.8M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
IPSC currently screens at market cap $47.8M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the IPSC and PATH stock pages for the full models.
Not investment advice.